NASDAQ:MTEMMolecular Templates Stock Price, Forecast & News

Molecular Templates' stock was trading at $13.22 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, MTEM shares have increased by 21.4% and is now trading at $16.05. View which stocks have been most impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Molecular Templates in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Molecular Templates.

Molecular Templates is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Molecular Templates.

Molecular Templates Inc (NASDAQ:MTEM) posted its quarterly earnings data on Tuesday, May, 12th. The biotechnology company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.30) by $0.18. The biotechnology company had revenue of $4.14 million for the quarter, compared to analyst estimates of $10.48 million. Molecular Templates had a negative return on equity of 76.76% and a negative net margin of 439.48%. View Molecular Templates' earnings history.

Molecular Templates's stock reverse split on the morning of Wednesday, August 2nd 2017. The 1-11 reverse split was announced on Tuesday, August 1st 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, August 1st 2017. An investor that had 100 shares of Molecular Templates stock prior to the reverse split would have 9 shares after the split.

4 equities research analysts have issued 1 year price targets for Molecular Templates' shares. Their forecasts range from $19.00 to $22.00. On average, they anticipate Molecular Templates' share price to reach $21.00 in the next year. This suggests a possible upside of 30.8% from the stock's current price. View analysts' price targets for Molecular Templates.

Press coverage about MTEM stock has trended negative on Thursday, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Molecular Templates earned a news impact score of -2.8 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news aboutMolecular Templates.

Molecular Templates saw a drop in short interest in April. As of April 30th, there was short interest totaling 1,470,000 shares, a drop of 13.5% from the April 15th total of 1,700,000 shares. Based on an average trading volume of 278,800 shares, the short-interest ratio is presently 5.3 days. Approximately 5.3% of the shares of the stock are short sold. View Molecular Templates' Current Options Chain.

Some companies that are related to Molecular Templates include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Immunomedics (IMMU). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Molecular Templates investors own include ZIOPHARM Oncology (ZIOP), Novavax (NVAX), Gilead Sciences (GILD), Synergy Pharmaceuticals (SGYP), TG Therapeutics (TGTX), CEL-SCI (CVM), SLS International (SLS), Amarin (AMRN), Corbus Pharmaceuticals (CRBP) and Exelixis (EXEL).

Molecular Templates trades on the NASDAQ under the ticker symbol "MTEM."

Molecular Templates' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.35%), Geode Capital Management LLC (0.77%), Telemark Asset Management LLC (0.77%), State Street Corp (0.71%), Monashee Investment Management LLC (0.40%) and Nuveen Asset Management LLC (0.26%). Company insiders that own Molecular Templates stock include Associates LLC Cdk, David Hirsch, Kevin M Lalande, Longitude Capital Partners Iii and Scott D Morenstein. View institutional ownership trends for Molecular Templates.

MTEM stock was sold by a variety of institutional investors in the last quarter, including Monashee Investment Management LLC, Two Sigma Investments LP, Morgan Stanley, Mackenzie Financial Corp, Invesco Ltd., UBS Group AG, Russell Investments Group Ltd., and Strs Ohio. View insider buying and selling activity for Molecular Templates.

MTEM stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Telemark Asset Management LLC, Deutsche Bank AG, JPMorgan Chase & Co., Hancock Whitney Corp, Geode Capital Management LLC, State Street Corp, and Nuveen Asset Management LLC. Company insiders that have bought Molecular Templates stock in the last two years include Associates LLC Cdk, David Hirsch, Longitude Capital Partners Iii, and Scott D Morenstein. View insider buying and selling activity for Molecular Templates.

Shares of MTEM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MTEM stock can currently be purchased for approximately $16.05.

Molecular Templates has a market capitalization of $733.65 million and generates $22.27 million in revenue each year. The biotechnology company earns $-69,420,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis. Molecular Templates employs 68 workers across the globe.

The official website for Molecular Templates is www.mtem.com.

Molecular Templates' mailing address is 9301 AMBERGLEN BLVD. SUITE 100, AUSTIN TX, 78729. The biotechnology company can be reached via phone at 512-869-1555 or via email at [email protected]